Company Filing History:
3 out of 120 
2 out of 33 
2 out of 26 Years Active: 2017-2024
Title: Innovations and Contributions of Jijun Li
Introduction
Jijun Li is a notable inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. With a total of three patents to his name, his work has garnered attention in the scientific community.
Latest Patents
Jijun Li's latest patents include an iminosulfanone compound that acts as a bromodomain protein inhibitor. This invention relates to a pharmaceutical composition and medical use of the compound, which is represented by a specific formula. Another significant patent is for a quinazoline derivative, which includes a preparation method and its application in drug development for curing and preventing tumors. This compound has shown the ability to irreversibly prevent EGFR phosphorylation, effectively inhibiting cancer cell signal transduction and demonstrating higher anti-tumor activity both in vitro and in vivo.
Career Highlights
Throughout his career, Jijun Li has worked with prominent companies in the pharmaceutical industry. Notable among these are Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Centaurus Biopharma Co., Ltd. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Jijun Li has collaborated with several professionals in his field, including Yan Zhu and Huting Wang. These collaborations have likely enhanced his research and development efforts, leading to impactful innovations.
Conclusion
Jijun Li's contributions to pharmaceutical innovations, particularly in cancer treatment, highlight his role as a significant inventor in the industry. His patents reflect a commitment to advancing medical science and improving patient outcomes.